World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
111
Citations
47833
World Ranking
5317
National Ranking
2870

Jan A. Burger publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jan A. Burger sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 741 publications — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jan A. Burger D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jan A. Burger sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 111 D-Index — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Jan A. Burger is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on Medicine, with a substantial contribution to related subfields such as Genetics, Hematology, Pathology and Forensic Medicine, Immunology, and Molecular Biology.

Their work extensively covers topics including Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, Acute Myeloid Leukemia Research, Immunodeficiency and Autoimmune Disorders, Acute Lymphoblastic Leukemia Research, and Advanced Breast Cancer Therapies.

Burger has published in several prominent scientific venues. Frequent publication venues include:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • HemaSphere
  • Leukemia
  • Leukemia & lymphoma/Leukemia and lymphoma

Some of Burger's recent papers are:

  • Treatment of Chronic Lymphocytic Leukemia, 2020, New England Journal of Medicine
  • 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial, 2020, The Lancet Haematology
  • Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia, 2022, Blood Advances
  • Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study, 2020, Clinical Cancer Research
  • Molecular map of chronic lymphocytic leukemia and its impact on outcome, 2022, Nature Genetics

Burger frequently collaborates with researchers such as:

  • Alessandra Ferrajoli
  • Nitin Jain
  • William G. Wierda
  • Hagop M. Kantarjian
  • Tapan M. Kadia

The body of Burger's research demonstrates a focus on the genetic and molecular basis of hematologic malignancies as well as clinical approaches to treatment. Their work intersects fundamental biology and clinical investigations, contributing knowledge to the application of novel therapies in leukemia and lymphoma management.

Best Publications

  • Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Ian W. Flinn

  • Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

    Jan A. Burger;Alessandra Tedeschi;Paul M. Barr;Tadeusz Robak

  • CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment.

    Jan A. Burger;Thomas J. Kipps;Thomas J. Kipps

  • Mesenchymal precursor cells in the blood of normal individuals

    Nathan J Zvaifler;Lilla Marinova-Mutafchieva;Gill Adams;Christopher J Edwards

  • Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.

    Jan A. Burger;Nobuhiro Tsukada;Meike Burger;Nathan J. Zvaifler

  • Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Jan A. Burger

  • The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

    Sabine Ponader;Shih Shih Chen;Joseph J. Buggy;Kumudha Balakrishnan

  • Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

    Susan O'Brien;Richard R Furman;Steven E Coutre;Jeff P Sharman

  • The microenvironment in mature B-cell malignancies: a target for new treatment strategies

    Jan A. Burger;Paolo Ghia;Andreas Rosenwald;Federico Caligaris-Cappio

  • The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

    Julia Hoellenriegel;Sarah A. Meadows;Mariela Sivina;William G. Wierda

  • Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.

    Jan A. Burger;Meike Burger;Meike Burger;Thomas J. Kipps

  • CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers

    J A Burger;A Peled

  • Ibrutinib and venetoclax for first-line treatment of CLL

    Nitin Jain;Michael Keating;Philip Thompson;Alessandra Ferrajoli

  • ICOS deficiency is associated with a severe reduction of CXCR5+CD4 germinal center Th cells.

    Lukas Bossaller;Jan Andreas Burger;Ruth Draeger;Bodo Grimbacher

  • Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

    Antonina V. Kurtova;Kumudha Balakrishnan;Rong Chen;Wei Ding

  • Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

    Farhad Ravandi;Mona Lisa Alattar;Michael R. Grunwald;Michelle A. Rudek

  • Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

    Jan A Burger;Michael J Keating;William G Wierda;Elena Hartmann

  • Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

    Jan A. Burger;Paul M. Barr;Tadeusz Robak;Carolyn Owen

  • B cell receptor signaling in chronic lymphocytic leukemia.

    Jan A. Burger;Nicholas Chiorazzi

  • Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

    Talha Munir;Jennifer R. Brown;Susan O'Brien;Jacqueline C. Barrientos

Frequent Co-Authors

William G. Wierda
William G. Wierda The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Alessandra Ferrajoli
Alessandra Ferrajoli The University of Texas MD Anderson Cancer Center
Michael J. Keating
Michael J. Keating The University of Texas MD Anderson Cancer Center
Zeev Estrov
Zeev Estrov The University of Texas MD Anderson Cancer Center
Nitin Jain
Nitin Jain The University of Texas MD Anderson Cancer Center
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare but seeking alternatives to traditional medical school, a wide range of online degrees and career pathways are available. Many of these programs offer flexible schedules and accelerated formats, making them ideal for busy professionals or career changers.

For example, individuals interested in preventive health and wellness may consider online nutrition degree programs, which delve into the science of diet and its impact on health outcomes. Those aiming for healthcare leadership roles might pursue one of the cahme accredited online mha programs list to gain critical management expertise.

Nurses looking to advance their careers without spending extra time in clinical settings can explore online rn to bsn programs no clinicals, while experienced nurses wanting to reach the top of clinical practice can find expedited options with the fastest dnp program choices.

Each of these online pathways opens the door to meaningful healthcare careers, offering accessible and respected routes to advancement in the medical field.

Best Scientists Citing Jan A. Burger

Trending Scientists

Recently Published Articles